• CDK4/6 and BET Inhibition Synergizes to Suppress EMT in PDAC

  2026-06-11

  Gu et al. (2025) demonstrate that combined inhibition of CDK4/6 and BET proteins synergistically restricts pancreatic tumor progression and reverses epithelial-mesenchymal transition (EMT) by modulating the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight addresses the limitations of CDK4/6 inhibitor monotherapy and suggests a more effective approach for targeting EMT in pancreatic ductal adenocarcinoma.

• Pyridostatin TFA: G-Quadruplex Stabilizer in Cancer & Neurob

  2026-06-10

  Pyridostatin TFA is a synthetic G-quadruplex stabilizer used in telomere biology and cancer cell growth inhibition. It selectively binds G-quadruplex DNA, disrupts telomere function, and demonstrates high selectivity against cancer cell lines. Its mechanism and applications are supported by recent evidence linking G-quadruplex modulation to protein aggregation in neurodegenerative disease.

• RNA Pol II Inhibition Triggers Apoptosis Beyond Transcriptio

  2026-06-10

  Harper et al. (2025) reveal that inhibition of RNA polymerase II (RNA Pol II) induces apoptosis through active signaling pathways, independent of transcriptional shutdown. This discovery reframes how cell death is understood in DNA damage response research and may inform future cancer biology workflows.

• Best Practices for Apoptosis Assays Using MCL-1 inhibitor A-

  2026-06-09

  This in-depth guide addresses common laboratory challenges in apoptosis and mitochondrial assays, using MCL-1 inhibitor A-1210477 (SKU B6011) as a model solution. Through real-world scenarios, the article demonstrates evidence-based strategies that enhance reliability and interpretability in cancer research workflows.

• Ceftolozane Sulfate: Precision Antipseudomonal Assays and Cl

  2026-06-09

  Explore the scientific foundations and translational applications of Ceftolozane sulfate in resistant Pseudomonas aeruginosa research. This in-depth guide demystifies its unique PBP3-targeted mechanism and provides actionable insight for assay optimization.

• BIBP 3226 trifluoroacetate: Precision in NPY/NPFF System Res

  2026-06-08

  BIBP 3226 trifluoroacetate empowers researchers to dissect the NPY/NPFF axis with high specificity, unlocking advanced models for anxiety, analgesia, and cardiovascular regulation. Its validated performance in stem cell coculture and signaling pathway studies sets a new benchmark for reproducible discovery.

• Ibuprofen in Translational Cancer Research: Mechanisms and A

  2026-06-08

  Explore the multifaceted role of Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) as an anti-proliferative agent in colon cancer research, with advanced insight into its mechanism and assay design. Uncover practical guidance for translational workflows and unique scientific findings.

• AP20187: Chemical Inducer of Dimerization for Precision Cont

  2026-06-07

  AP20187 empowers researchers with on-demand control over protein interactions in conditional gene expression systems, unlocking precision in metabolic, hematopoietic, and cancer biology studies. Its high solubility, rapid cell permeability, and proven in vivo efficacy make it a gold-standard chemical inducer of dimerization for advanced gene therapy and signaling pathway activation.

• AG-126 (Tyrphostin AG-126): Precision ERK Inhibition in Neur

  2026-06-06

  AG-126 (Tyrphostin AG-126) stands out as a highly selective ERK1/2 inhibitor, enabling researchers to dissect MAPK/ERK pathway dynamics in models of neuroinflammation and autism-related behaviors. Discover workflow optimizations, troubleshooting strategies, and practical cross-links to published breakthroughs that leverage AG-126 for reproducible, high-impact results.

• Anlotinib Hydrochloride (SKU C8688): Precision in Angiogenes

  2026-06-05

  This scenario-driven guide equips biomedical researchers and lab technicians with evidence-based protocols for using Anlotinib hydrochloride (SKU C8688) in cell viability, proliferation, and angiogenesis assays. Drawing on peer-reviewed data and real lab challenges, it demonstrates how Anlotinib hydrochloride delivers reproducible, sensitive, and safe results—making it an indispensable tool for modern cancer research workflows.

• Advanced In Vitro Approaches for Evaluating PARP Inhibitors

  2026-06-05

  Schwartz's dissertation introduces a nuanced in vitro framework for distinguishing drug-induced proliferation arrest from cell death in cancer models, emphasizing the distinct measurement of relative and fractional viability. These methodological refinements enable more precise evaluation of novel PARP inhibitors, such as AZD2461, and have significant implications for breast cancer research and drug resistance studies.

• RNASEH1-AS1 as Prognostic lncRNA and Target in Hepatocellula

  2026-06-04

  This study identifies the long non-coding RNA RNASEH1-AS1 as a robust prognostic biomarker and oncogenic target in hepatocellular carcinoma (HCC). Through integrative bioinformatics and experimental validation, the research delineates RNASEH1-AS1's diagnostic potential and mechanistic involvement in tumor progression, highlighting its value for future RNA-focused cancer studies.

• ABT-263 (Navitoclax): Redox Imaging and Mitochondrial Dynami

  2026-06-04

  Explore how ABT-263 (Navitoclax) enables advanced mitochondrial and metabolic profiling in cancer biology using optical redox ratio imaging. This article reveals assay design insights and mechanistic nuances not covered in standard apoptosis workflows.

• KU-60019: Precision ATM Inhibition for Synergistic Cancer St

  2026-06-03

  Explore how KU-60019, a potent ATM kinase inhibitor, enables next-generation assay design and combination therapies, extending far beyond radiosensitization. This article delivers actionable insights for advanced cancer research.

• Targeting BCL-XL and MCL-1 in Glioblastoma: Insights from BH

  2026-06-03

  The reference study identifies elevated BCL-XL and MCL-1 expression as a key vulnerability in glioblastoma, rendering these tumors highly sensitive to BH3-mimetic–mediated apoptosis. Sequential inhibition of these anti-apoptotic proteins produces robust tumor control in preclinical models, supporting a rational strategy to overcome therapy resistance in GBM and potentially other malignancies.

16321 records 7/1089 page Previous Next First page 上5页 678910 下5页 Last page